• In the literature, up to 45% of neuroendocrine tumor (NET) patients who are treated with 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) do not receive the intended cumulative activity of 29.6 GBq (800 mCi). (snmjournals.org)
  • In NET patients treated with a cumulative activity of less than 29.6 GBq of 177 Lu-DOTATATE, PRRT was less efficacious in tumor response and survival than in patients who received 29.6 GBq. (snmjournals.org)
  • For patients with metastatic disease, peptide receptor radionuclide therapy (PRRT) is an established treatment option ( 2 ). (snmjournals.org)
  • PRRT with radiolabeled somatostatin analogs targets somatostatin receptors that are frequently present on the NET cell membrane. (snmjournals.org)
  • Peptide receptor radionuclide therapy (PRRT) is a type of radionuclide therapy, using a radiopharmaceutical that targets peptide receptors to deliver localised treatment, typically for neuroendocrine tumours (NETs). (wikipedia.org)
  • A key advantage of PRRT over other methods of radiotherapy is the ability to target delivery of therapeutic radionuclides directly to the tumour or target site. (wikipedia.org)
  • When paired with alpha or beta emitters, therapy can be achieved, as in PRRT. (wikipedia.org)
  • The current generation of PRRT targets somatostatin receptors, with a range of analogue materials such as octreotide and other DOTA compounds. (wikipedia.org)
  • When it comes to comparing these two PRRT, Y-labeled and Lu-labeled PRRTs, it appears that Y-labeled is more effective for larger tumors, while Lu-labeled is better for smaller and primary tumors. (wikipedia.org)
  • More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. (uni-wuerzburg.de)
  • Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. (uni-wuerzburg.de)
  • COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEPNET. (endocrine-abstracts.org)
  • Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant 177 Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors. (nih.gov)
  • UChicago Medicine was one of the first hospitals to offer peptide receptor radionuclide therapy (PRRT) to treat neuroendocrine tumors. (uchicagomedicine.org)
  • Additionally he leads the PRRT (peptide receptor radionuclide therapy) program for neuroendocrine tumors and PSMA Radioligand Therapy at UCSF. (ucsf.edu)
  • In January 2018, the FDA approved Lutetium 177 ( 177 Lu) Dotatate, a peptide receptor radionuclide therapy (PRRT), for the treatment of patients with somatostatin receptor-positive gastroenteropancreatic NETs. (onclive.com)
  • Promising new treatments for neuroendocrine tumors, such as Peptide Receptor Radionuclide Therapy (PRRT). (ucsf.edu)
  • 3. Combination Therapies with PRRT. (klinikum-westfalen.de)
  • Following her surgical oncology training at Memorial Sloan Kettering Cancer Center, she built a multidisciplinary neuroendocrine program at Indiana University to expand surgical options for NET patients to include single or multi-visceral organ transplantation, established Gallium 68 PET/CT imaging and brought Lu-177 peptide receptor radionuclide therapy (PRRT) to patients in the Midwest. (carcinoid.org)
  • As with most, if not all, of the treatment options open to neuroendocrine tumor patients, there are risks associated with using PRRT to treat metastasized tumors. (prrtinfo.org)
  • PRRT info.org is a site for patients considering PRRT (Peptide Receptor Radionuclide Therapy) treatment in Germany written by patients for patients. (prrtinfo.org)
  • It is also known as "targeted radionuclide therapy", "peptide receptor radionuclide therapy (PRRT)" "somatostatin receptor radioligand therapy. (intheranostics.com)
  • 4) Leutitium-177 labelled Peptide Receptor Radionuclide Therapy (PRRT) is a promising treatment option in neuroendocrine tumors. (examyear.com)
  • Several theranostic ligands, including 177 Lu-DOTATATE for peptide radioreceptor therapy (PRRT) were successfully translated to the clinic. (thieme-connect.de)
  • Aim: The most suitable method for assessment of response to peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NET) is still under debate. (hs-hannover.de)
  • In this study we aimed to compare size (RECIST 1.1), density (Choi), Standardized Uptake Value (SUV) and a newly defined ZP combined parameter derived from Somatostatin Receptor (SSR) PET/CT for prediction of both response to PRRT and overall survival (OS). (hs-hannover.de)
  • Provide Nuclear Medicine Technologists education regarding neuroendocrine tumor imaging and treatments, with a focus on theranostics and Peptide Receptor Radionuclide Therapy (PRRT). (site.com)
  • Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with no prior history of peptide receptor radionuclide therapy (PRRT naive). (marketsampler.com)
  • In NET, radioligand therapy (also known as PRRT - peptide-receptor radionuclide therapy) is well-established and may achieve high rates of long lasting tumor remission and stabilization. (uniklinik-freiburg.de)
  • PRRT ) making a 'theranostic' approach to diagnosing, treating and surveillance Neuroendocrine Cancer patients with somatostatin receptor positive tumours. (ronnyallan.net)
  • Also worth pointing out that JR11 is also associated with the radionuclide used in PRRT clinical trial of Lutetium-177 OPS-201 (Satoreotide) - I wrote about that here . (ronnyallan.net)
  • The NETTER-1 trial has recently shown the efficacy of 177 Lu-DOTATATE in association with Octreotide (OCT) in somatostatin receptor positive midgut NETs, progressing to OCT. The aim of this analysis was to evaluate the role of SSA in association to PRRT beyond PD or after switch to other SSA at PD. (esmo.org)
  • The most of pts (82.9% in S1 and 86.3% in S2) received PRRT with alternate radionuclides ( 90 Y/ 177 Lu). (esmo.org)
  • Neuroendocrine tumors (NETs) originate predominantly from neuroendocrine cells in the bronchopulmonary system, the gastrointestinal tract, and the pancreas ( 1 ). (snmjournals.org)
  • Data suggest that the gene for MEN-1, called MENIN, is also involved in the pathogenesis of at least one third of sporadic neuroendocrine tumors (NETs), including gastrinomas. (medscape.com)
  • What have some of the trends been in the difficult-to-treat cancers, such as pancreatic cancer and neuroendocrine tumors (NETs)? (onclive.com)
  • Neuroendocrine tumors, or NETs, are tumors that form in neuroendocrine cells. (uchicagomedicine.org)
  • At UChicago Medicine, treatment for NETs often includes surgery, even for tumors that have spread to other organs. (uchicagomedicine.org)
  • Neuroendocrine tumors (NETS) are rare and complex. (nanets.org)
  • NETs are tumors that originate in neuroendocrine cells or cells that produce hormones in response to signals from the nervous system. (nanets.org)
  • NETs can be found anywhere in the body where there are neuroendocrine cells. (nanets.org)
  • In neuroendocrine tumors (NETs), liver metastases (LM) represent the most crucial prognostic factor, irrespective of the primary tumor site. (oaepublish.com)
  • At diagnosis, about 65-95% of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show hepatic metastasis. (oaepublish.com)
  • Neuroendocrine tumors (NETs) are rare neoplasms originating from diffuse neuroendocrine cells. (oaepublish.com)
  • [ 1 ] Basically, NETs are classified according to tumor differentiation and site of occurrence. (oaepublish.com)
  • [ 2 ] Well- to moderately differentiated neuroendocrine neoplasms (WMD-NEN) are a highly heterogeneous group of tumors comprising low-grade (G1) and intermediate-grade (G2) NETs of the gastrointestinal tract, typical and atypical carcinoids of the lung and thymus, and other cancers such as medullary thyroid carcinoma and pheochromocytoma/paraganglioma. (oaepublish.com)
  • More recently, on August 13, 2021, the FDA approved belzutifan (Welireg) for the treatment of patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic NETs that do not require immediate surgery, Soares says. (onclive.com)
  • Beyond this, investigational therapies are emerging as potential options for patients with pancreatic NETs. (onclive.com)
  • His team investigates the cellular and molecular basis of neuroendocrine tumors (NETs), pituitary tumors and pancreatic adenocarcinoma, and the role of metabolic and hormonal alterations in cancer. (bioscientifica.com)
  • LUTATHERA® (lutetium Lu 177 dotatate) is a prescription therapy used to treat adults with a special type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs). (muschealth.org)
  • This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs. (marketsampler.com)
  • This works because some tumours have an abundance (overexpression) of peptide receptors, compared to normal tissue. (wikipedia.org)
  • With a gamma emitter as the radionuclide, the technique can be used for imaging with a gamma camera or PET scanner to locate tumours. (wikipedia.org)
  • Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. (endocrine-abstracts.org)
  • Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT). (harvard.edu)
  • A dosimetric comparison of systemic peptide receptor radionuclide therapy and intra-arterial peptide receptor radionuclide therapy in patients with liver dominant gastroenteropancreatic neuroendocrine tumours. (harvard.edu)
  • Although most guidelines suggest performing a positron emission tomography/computed tomography (PET/CT) with somatostatin receptor (SSTR) ligands for staging of pulmonary carcinoid tumours (PC), only a limited. (springeropen.com)
  • 5458 - Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen. (esmo.org)
  • 3253 - The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours. (esmo.org)
  • Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (endocrine-abstracts.org)
  • Prospective evaluation of the utility of concurrent 18F-FDG PET/CT and 68Ga-DOTA-TOC imaging in gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): The PETNET study. (endocrine-abstracts.org)
  • Imaging of Small-Bowel Neuroendocrine Neoplasms: AJR Expert Panel Narrative Review. (harvard.edu)
  • Segmentation of neuroendocrine neoplasms (NENs) in [ 64 Cu]Cu-DOTATATE positron emission tomography makes it possible to extract quantitative measures useable for prognostication of patients. (springeropen.com)
  • Highly aggressive, poorly differentiated neoplasms were defined as Grade-3 neuroendocrine carcinomas (NECs) when originating from the gastrointestinal tract, or as small- or large-cell NECs when appearing in the lung. (oaepublish.com)
  • MEN-1 is known to cause multiple tumors within the pancreas, pituitary, parathyroid, and adrenal glands through an autosomal dominant pattern of inheritance. (medscape.com)
  • Gastrinomas are neuroendocrine tumors that are usually found in the duodenum wall (approximately 50%) or in the pancreas. (medscape.com)
  • [ 5 ] When gastrinomas are found in the pancreas, they are non-beta islet cell tumors. (medscape.com)
  • They are distributed throughout the body, but the most common places for tumors to develop from them are in the lungs, small intestines and pancreas. (mdanderson.org)
  • The tumors begin in neuroendocrine cells - which have characteristics of nerve and hormone-producing cells - and can arise in multiple sites in the body, most often in the gastrointestinal tract, lungs, and pancreas. (dana-farber.org)
  • The study enrolled 197 patients with advanced extra-pancreatic neuroendocrine tumors (which arise outside the pancreas) and 93 patients with pancreatic neuroendocrine tumors. (dana-farber.org)
  • Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. (medscape.com)
  • Challenges Staging Neuroendocrine Tumors of the Pancreas, Jejunum and Ileum, and Appendix. (ucsf.edu)
  • These tumors can be in the stomach, intestines or pancreas. (muschealth.org)
  • Overview of Carcinoid Tumors Carcinoid tumors develop from neuroendocrine cells in the gastrointestinal tract (90%), pancreas, pulmonary bronchi, and rarely the genitourinary tract. (msdmanuals.com)
  • Therapeutic options in patients with progressive and disseminated metastatic neuroendocrine gastroenteropancreatic (GEP) tumors are often limited, and prognosis is often poor ( 1 , 2 ). (snmjournals.org)
  • Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. (uchicago.edu)
  • The randomized controlled phase III Neuroendocrine Tumors Therapy (NETTER-1) trial evaluated the efficacy and safety of 177Lu-DOTATATE as compared with high-dose octreotide long-acting repeatable (LAR) in patients with advanced progressive somatostatin-receptor positive midgut neuroendocrine tumors. (wikipedia.org)
  • The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. (ucsf.edu)
  • The study randomized 229 patients with well-differentiated metastatic or locally advanced inoperable midgut neuroendocrine tumors to receive 4 intravenous administrations (every 8 weeks) of the peptide receptor radionuclide therapy (plus best supportive care, including standard-dose octreotide long-acting repeatable [LAR]) or high-dose octreotide LAR alone. (ascopost.com)
  • Jennifer Chan, MD, MPH , director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber , will present the findings of the CABINET trial at the annual European Society for Medical Oncology (ESMO) Congress on October 22, 2023, in Madrid, Spain. (dana-farber.org)
  • DelveInsight's report titled "Neuroendocrine Tumors Pipeline Insight 2023" offers extensive information on more than 55+ companies and over 60+ pipeline drugs in the field of Neuroendocrine Tumors research. (marketsampler.com)
  • The results of the phase III NETTER-1 trial, recently published in The New England Journal of Medicine, 1 have been met with great interest by clinicians who treat neuroendocrine tumors. (ascopost.com)
  • 8. Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study. (klinikum-westfalen.de)
  • What is a Radioligand Therapy? (uniklinik-freiburg.de)
  • b) A relatively novel radioligand therapy is available for metastasized prostate cancer: Here a radioligand is used which specifically binds to the so-called prostate-specific membrane antigen (PSMA), that is overexpressed in prostate cancer. (uniklinik-freiburg.de)
  • 1) There is overexpression of SSTR receptor 2, 3, 5 by neuroendocrine tumor. (examyear.com)
  • In a head-to-head comparison of two somatostatin receptor (SSTR) imaging agents, 68Ga-DOTA-JR11 PET/CT performed better than 68Ga-DOTATATE PET/CT in detecting liver metastases, with a better tumor-to-background ratio, according to research published in the June issue of The Journal of Nuclear Medicine . (ronnyallan.net)
  • METHODS: Between March 2018 and December 2021, a total of 168 patients were referred to 177Lu-PSMA therapy in our department and received a mean total dose of 21.9 GBq (three cycles in mean). (bvsalud.org)
  • About 12,000 people will be diagnosed with neuroendocrine tumors - sometimes called carcinoid tumors - each year. (mdanderson.org)
  • Neuroendocrine Tumors of the Bronchopulmonary System (Typical and Atypical Carcinoid Tumors): Current Strategies in Diagnosis and Treatment. (karger.com)
  • Carcinoid tumors. (medscape.com)
  • Serotonin , the primary hormone produced by carcinoid tumors, acts on smooth muscle to cause diarrhea, colic, and malabsorption. (msdmanuals.com)
  • In a large multi-institutional German study, the newer agent almost doubled the progression-free survival time over 90-Y dotatate and improved overall survival at 4 years from about 40% to approximately 70%, with the greatest effect seen in small bowel neuroendocrine tumors. (ascopost.com)
  • The somatostatin analogue affects biodistribution of the radionuclide, and therefore how effectively any treatment effect can be targeted. (wikipedia.org)
  • MIBG can be labeled with 131 I, which has a long half-time (8 d) and a maximal electron range of about 2.4 mm and is established in the treatment of tumors derived from the neural crest, such as GEP tumors ( 11 ). (snmjournals.org)
  • We have more neuroendocrine tumor treatment options today than ever before. (mdanderson.org)
  • Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives. (nih.gov)
  • The results suggest cabozantinib, which has been approved by the U.S. Food and Drug Administration for some patients with renal cell carcinoma, hepatocellular carcinoma, or thyroid cancer, can benefit patients with neuroendocrine tumors that continue to grow and spread after previous treatment, researchers say. (dana-farber.org)
  • Treatments may include surgery, targeted therapy, peptide receptor radionuclide therapy, chemotherapy, or other local treatment approaches depending on the location and stage of the cancer. (dana-farber.org)
  • Cabozantinib significantly improved outcomes in patients with previously treated extra-pancreatic and pancreatic neuroendocrine tumors and may become a new treatment option for patients. (dana-farber.org)
  • Background \(^{177}\)Lu is used in peptide receptor radionuclide therapies for the treatment of neuroendocrine tumors. (uni-wuerzburg.de)
  • Now molecular classifications are guiding treatment decisions as advances in subgroups of patients drive the momentum of the rapid changes across tumor types. (onclive.com)
  • Practical Considerations for Implementation of 177 Lu-DOTATATE Neuroendocrine Tumor Treatment Programs. (nih.gov)
  • They work together to accurately diagnose neuroendocrine tumors, and to determine the most effective treatment for each patient. (uchicagomedicine.org)
  • The primary goals are to evaluate possible liver, bone marrow and kidney toxicity after hepatic arterial injection and evaluate imaging tumor response to 90Y-DOTA-TOC hepatic arterial injection three months after treatment. (netrf.org)
  • NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. (netrf.org)
  • NANETS' 400+ members represent many of the most widely recognized and respected physicians, surgeons, allied healthcare providers and researchers in the world, all working toward the same goal: to improve treatment outcomes and care for patients living with neuroendocrine tumors. (nanets.org)
  • Methods: First, to determine comparable injected activities from 177Lu- and 225Ac-PSMA-617, ex vivo biodistribution studies were performed at 5 time points after treatment of C4-2 subcutaneous tumor-bearing NSG mice. (bvsalud.org)
  • Treatment efficacy was evaluated using whole-body tumor burden and overall survival. (bvsalud.org)
  • When treated at 5 wk after inoculation (macroscopic disease), all treatment groups showed retarded tumor growth and improved survival, with no significant differences between 225Ac alone and administration of half the 225Ac activity in tandem with 177Lu (overall survival, 7.9 wk for nontreatment, 10.3 wk for 177Lu, 14.6 wk for 225Ac alone, and 13.2 wk for tandem therapy). (bvsalud.org)
  • Conclusion: Treatment of a disseminated model of prostate cancer with simultaneous 225Ac- and 177Lu-PSMA-617 results in significantly decreased tumor growth compared with 177Lu, which was ineffective as a single agent against microscopic lesions. (bvsalud.org)
  • Offering comprehensive evaluations and personalized treatment plans, the Center for Neuroendocrine Tumors includes a multidisciplinary team that enables patients with any type of neuroendocrine tumor to receive expert, team-based care. (ucsf.edu)
  • Her mission was/is to merge what has historically been an aggressive surgical managerial approach to NET patients with emerging therapies and clinical trials that will define evidence-based treatment guidelines to optimize outcomes for patients. (carcinoid.org)
  • Lutetium-177 PSMA therapy is an innovative and effective treatment that is increasingly used to treat metastatic castration-resistant prostate cancer. (intheranostics.com)
  • It is a treatment method used in neuroendocrine tumors. (intheranostics.com)
  • Radioactive iodine therapy is a standard practice that has been frequently preferred in the treatment of benign and malignant (cancer) diseases of the thyroid since the 1940's and has been shown to have an effect on survival in patients with thyroid cancer. (intheranostics.com)
  • Radiotheranostics are small-molecule or carrier-bound radiopharmaceuticals that can be used for diagnostic imaging and radionuclide therapy, especially for the treatment of various tumour diseases. (thieme-connect.de)
  • We are also progressing towards creating a trial using PSMA-617 as a targeted therapy treatment. (ucsf.edu)
  • Therapy plans vary depending on how your body responds to the treatment. (muschealth.org)
  • Requests for therapy will be reviewed by MUSC nuclear medicine physicians to determine treatment eligibility. (muschealth.org)
  • DelveInsight's Neuroendocrine Tumors Pipeline analysis depicts a robust space with 55+ active players working to develop 60+ pipeline treatment therapies. (marketsampler.com)
  • The therapy consists of several applications (cycles) of therapy in intervals of 2-3 months: In case of NET-treatment with the radioligand Lutetium-177-DOTATATE, approx. (uniklinik-freiburg.de)
  • The synthesis and applications of the peptides are gaining increasing popularity as a result of the developments in biotechnology and bioengineering areas and for a number of research purposes including cancer diagnosis and treatment, antibiotic drug development, epitope mapping, production of antibodies, and vaccine design. (intechopen.com)
  • For neuroendocrine cancer patients with liver metastases, a new radiopharmaceutical, 68Ga-DOTA-JR11, has shown excellent imaging performance in tumor detection, staging, and restaging, providing important information to guide treatment. (ronnyallan.net)
  • It may also change the treatment strategy, especially when partial resection or local therapy for liver metastasis is considered. (ronnyallan.net)
  • Patients receiving a reduced activity had more bone metastases, a lower body mass index and albumin level, a higher alkaline phosphatase level, and fewer grade 1 tumors than the 350 patients included in the control group. (snmjournals.org)
  • 7. Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy. (klinikum-westfalen.de)
  • While the radiopharmaceuticals showed similar lesion uptake for primary tumors and lymph node metastases on both patient-based and lesion-based comparisons, the target-to-background ratio of liver lesions was significantly higher on 68Ga-DOTA-JR11. (ronnyallan.net)
  • An intestinal carcinoid does not usually cause carcinoid syndrome unless hepatic metastases have occurred because metabolic products released by the tumor are rapidly destroyed by blood and liver enzymes in the portal circulation (eg, serotonin by hepatic monoamine oxidase). (msdmanuals.com)
  • Basically, neuroendocrine tumors are cancers that can develop anywhere endocrine cells are present. (mdanderson.org)
  • Associate Professor Liz Caldon runs a basic and translational research program on estrogen receptor positive (ER+) breast cancer and basal-like breast cancers. (bioscientifica.com)
  • Her group has built models of hormone therapy and CDK4-6 inhibitor resistance to understand the evolution of ER+ breast cancers as they become refractory to standard of care therapies. (bioscientifica.com)
  • Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers. (prrtinfo.org)
  • At the 2017 Gastrointestinal Cancers Symposium, principal investigator of NETTER-1, Jonathan Strosberg, MD , of Moffitt Cancer Center in Tampa, Florida, brought listeners up-to-date on this effective second-line therapy and looked ahead to future treatments of neuroendocrine tumors. (ascopost.com)
  • The intent was to treat all patients because of uncontrolled tumor disease ( n = 21), contraindication to chemotherapy or surgery ( n = 7), or uncontrolled and badly tolerated clinical symptoms ( n = 4). (snmjournals.org)
  • Chemotherapy in well differentiated neuroendocrine tumors (NET) G1, G2, and G3: A narrative review. (endocrine-abstracts.org)
  • Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. (harvard.edu)
  • The type of systemic therapy used is dependent on the grade and proliferation of the tumor and includes somatostatin analogues, interferon, m-Tor and tyrosine kinase inhibitors, and chemotherapy. (oaepublish.com)
  • According to current, still preliminary data, the therapy may achieve a high rate of tumor response even in patients refractory to conventional chemotherapy. (uniklinik-freiburg.de)
  • chemotherapy may be used for malignant tumors. (msdmanuals.com)
  • The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer. (harvard.edu)
  • Immunogenomic Landscape of Neuroendocrine Prostate Cancer. (harvard.edu)
  • Dr. Hope's main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors. (ucsf.edu)
  • Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is a promising option for metastatic castration-resistant prostate cancer. (bvsalud.org)
  • Based on the recent literature, SST2 antagonists are superior to agonists in tumor uptake. (uni-wuerzburg.de)
  • PSMA PET/MRI demonstrating uptake in a high grade primary tumor. (ucsf.edu)
  • In addition, a new parameter named ZP, the product of Hounsfield unit (HU) and SUVmean (Standard Uptake Value) of a tumor lesion, was tested. (hs-hannover.de)
  • In the last part, information about cell-penetrating peptides that can be used as molecular carries is mentioned with providing classification and cellular uptake mechanism of them. (intechopen.com)
  • However, newly developed peptide antagonists, which recognize and then block SSTRs, have shown more favourable pharmacokinetics, better image contrast, higher tumor uptake, and better residence time in recent studies. (ronnyallan.net)
  • The first is local treatments , such as surgery , which focus on the tumor itself. (mdanderson.org)
  • We have a strong translation clinical research focus on novel radiotracers and targeted radionuclide treatments. (ucsf.edu)
  • Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant 225 Ac-DOTATATE Targeted Alpha Therapy and Capecitabine: A Real-world Scenario Management Based Long-term Outcome Study. (nih.gov)
  • Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. (nih.gov)
  • Lu-177 dotatate , a peptide receptor radionuclide therapy, consists of the somatostatin analog octreotate connected with the beta- and gamma-emitting radiopharmaceutical lutetium-177. (ascopost.com)
  • Dr. Loaiza-Bonilla posed the question of whether Lu-177 dotatate is more effective than a similar peptide receptor radionuclide therapy containing the radioisotope yttrium-90. (ascopost.com)
  • As both speakers indicated, peptide receptor radionuclide therapy (90-Y dotatate or Lu-177 dotatate ) is recommended for patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors that are progressing despite standard-dose long-acting somatostatin analog therapy and for pancreatic neuroendocrine tumors progressing after somatostatin analog therapy or everolimus (Afinitor). (ascopost.com)
  • Patients referred for therapy should have gastroenteropancreatic neuroendocrine tumors with evidence of disease progression, recent DOTATATE imaging, and appropriate blood counts, renal function, and liver function. (muschealth.org)
  • Although it had been in trial use for some years in Europe and elsewhere, the formal approval of 68Ga-DOTATATE has led to an increase in the development of other radionuclides, some in conjunction with therapeutic options (i.e. (ronnyallan.net)
  • Hence, we designed this prospective study to compare 68Ga-DOTATATE and 68Ga-DOTA-JR11 PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors. (ronnyallan.net)
  • For patients with different metastatic patterns, different peptides (DOTA-JR11 versus DOTATATE) should be used. (ronnyallan.net)
  • In liver-dominant disease, 68Ga-DOTA-JR11 may be a better choice in tumor staging and restaging compared to 68Ga-DOTATATE. (ronnyallan.net)
  • 2020) Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study. (ronnyallan.net)
  • Pejorative events were defined as side effects due to therapy, relapse in clinical symptoms, tumor progression, tumor laboratory marker increase, and death. (snmjournals.org)
  • A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators. (dana-farber.org)
  • The rapid evolution of clinical and pathological findings has hampered a systematic classification of this inhomogeneous family of tumors. (oaepublish.com)
  • Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. (ucsf.edu)
  • Dr Casey leads neuroendocrine tumour (NET) and endocrine cancer services in Cambridge and is the endocrine lead for the endocrine genetics service, encompassing both clinical practice and independently funded research in GIST, phaeochromocytoma and paraganglioma. (bioscientifica.com)
  • Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine. (thieme-connect.de)
  • The Program for Molecular Imaging and Targeted Therapy Lab involves a number of clinical trials focused on the translation of novel targeting imaging and therapy agents. (ucsf.edu)
  • The Neuroendocrine Tumors pipeline report encompasses detailed profiles of the pipeline drugs for Neuroendocrine Tumors, including information on Neuroendocrine Tumors clinical trials and nonclinical stage products. (marketsampler.com)
  • Although advances have been made in recent years, there remains a critical need for new and effective therapies for patients with advanced neuroendocrine tumors, particularly patients whose cancer has progressed on currently available options," said Chan. (dana-farber.org)
  • He serves as Chief of Nuclear Medicine at the San Francisco VA Medical Center and as chair of the Cancer Center's Molecular Imaging & Radionuclide Therapy Site Committee. (ucsf.edu)
  • Their discovery of aberrant splicing variants of neuropeptides (eg In1-ghrelin) and receptors (eg SST5TMD4) led to focus their research on the emerging pathophysiologic and oncogenic role of the dysregulation of RNA biology and surveillance mechanisms, particularly alternative splicing, in endocrine tumors and cancer. (bioscientifica.com)
  • CCF's Luncheon with the Experts series features physicians and healthcare professionals, support group leaders, patients, and colleagues who are key opinion leaders in the neuroendocrine cancer community worldwide. (carcinoid.org)
  • Its purpose is to damage cancer cells in the bone, causing the tumors to shrink or even disappear completely. (intheranostics.com)
  • Guidelines for radioiodine therapy of differentiated thyroid cancer. (thieme-connect.de)
  • Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. (thieme-connect.de)
  • Ease of access to thoracic and lung cancer care at locations throughout the Bay Area for convenient imaging, radiation therapy, and infusion therapy. (stanfordhealthcare.org)
  • A neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body's neuroendocrine system. (marketsampler.com)
  • The use of synthetic peptides approved by the health authorities for vaccine, for cancer, and in drug delivery systems is increasing with these developments. (intechopen.com)
  • It blocks the receptor for VEGF, a protein used to tap into the body's blood supply, as well as other receptors including c-MET, AXL, and RET that are key to tumor cell survival and metastasis. (dana-farber.org)
  • Primary outcomes were progression-free survival (PFS) and tumor response, and the secondary outcome was overall survival (OS). (snmjournals.org)
  • The North American Neuroendocrine Tumor Society's (NANETS) mission is to support outcomes for patients with neuroendocrine tumors through multidisciplinary medical education, NET related research, publication of guidelines and the exchange of knowledge and innovation. (nanets.org)
  • Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. (harvard.edu)
  • Management strategies of LM are heterogeneous and range from systemic therapy to liver-directed procedures. (oaepublish.com)
  • Radioligand therapies are well-tolerated systemic therapies used in metastasized disease. (uniklinik-freiburg.de)
  • Ectopic Cushing syndrome, tumor flow cytometry features, and overexpression of certain growth factors such as human epidermal growth factor receptor 2 (HER2/neu) are associated with aggressive gastrinomas and poor prognosis. (medscape.com)
  • For example, DOTA-lanreotide (DOTALAN) has a lower affinity for receptor 2 and a higher affinity for receptor 5 compared to DOTA-octreotide (DOTATOC). (wikipedia.org)
  • Two agents have been proposed for GEP tumor imaging: pentetreotide ([DTPA- d -Phe 1 ]octreotide, where DTPA is diethylenetriaminepentaacetic acid) ( 6 - 8 ) and metaiodobenzylguanidine (MIBG) ( 9 , 10 ). (snmjournals.org)
  • Octreotide labeling with 90 Y has recently been proposed for radionuclide therapy ( 12 - 16 ) but, to date, it is not commercially available in France. (snmjournals.org)
  • Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: how important is internal dosimetry? (scielo.org.za)
  • So a patient will go to the doctor, thinking they have a gallbladder issue, and it turns out to be a neuroendocrine tumor in the liver. (mdanderson.org)
  • Our interventional radiologists also have several technologies they can use to control individual tumors, particularly in the liver. (mdanderson.org)
  • Angiographic liver-directed techniques, such as transarterial embolization/chemoembolization and selective internal radiation therapy, offer excellent palliation for patients with liver-predominant disease. (oaepublish.com)
  • In highly selected cases, liver transplantation and peptide receptor radionuclide therapy are considered. (oaepublish.com)
  • Further, SUV values (max and mean) of the tumor were normalized to SUV of normal liver parenchyma. (hs-hannover.de)
  • Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. (harvard.edu)
  • At a median follow-up of 16.7 months, patients with pancreatic tumors who took cabozantinib had a PFS of 11.4 months, compared to 3.0 months for those who took a placebo. (dana-farber.org)
  • However, patients with high tumor accumulation and multiple lesions seemed to benefit from 90Y-DOTATOC, while patients with low tumor burden, solitary lesions and extra-hepatic disease experienced more favorable outcome on 177Lu-DOTATOC. (wikipedia.org)
  • In bone-dominant disease, we should probably stick to agonists, as 68Ga-DOTA-JR11 may underestimate tumor burden. (ronnyallan.net)
  • We compared the efficacy of radionuclide therapy with 111 In-pentetreotide and 131 I-metaiodobenzylguanidine (MIBG) in 20 patients (group A) with the outcome of similar patients who could not be treated for nonmedical reasons (group B, n = 12). (snmjournals.org)
  • However, the interplay of immune landscape and 177Lu-PSMA therapy efficacy is poorly understood. (bvsalud.org)
  • Proof of Therapeutic Efficacy of a (177)Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model. (thieme-connect.de)
  • Zollinger-Ellison syndrome (ZES) is a rare condition characterized by peptic ulcers that are refractory to conventional medical therapy. (medscape.com)
  • Funding is essential to continue support of basic and translational research to advance the medical field, expand the knowledge base and facilitate the understanding of neuroendocrine tumors. (nanets.org)
  • Consequently, radionuclide therapy may be proposed to patients with uncontrolled disease after conventional therapy ( 5 , 11 ). (snmjournals.org)
  • Multiple Endocrine Neoplasias types 1 and 2 (MEN1 and MEN2), hereditary paraganglioma - pheochromocytoma syndromes, and von Hippel-Lindau disease (VHL) are all examples of conditions that predispose people born with certain gene mutations to developing neuroendocrine tumors. (nanets.org)
  • Mice treated later in the disease progression and bearing macroscopic, millimeter-sized lesions experienced significant tumor growth retardation and survival benefit in both monoisotopic and tandem regimens of 177Lu and 225Ac. (bvsalud.org)
  • Specific interests of her group are the understanding of tumour cell evolution through single cell modelling, cell cycle based therapies, therapy repurposing, and the development of targeted approaches in therapy resistant disease. (bioscientifica.com)
  • While the name "neuroendocrine" implies that these tumors involve both nerve cells and hormones, they are mainly thought to come from endocrine cells. (mdanderson.org)
  • The hormones produced can vary depending on the place in the body where the tumor originates. (mdanderson.org)
  • The syndrome results from vasoactive substances (including serotonin , bradykinin, histamine, prostaglandins, polypeptide hormones) secreted by the tumor, which is typically a metastatic intestinal carcinoid. (msdmanuals.com)
  • The radionuclide delivers the actual therapeutic effect (or emission, such as photons, for imaging). (wikipedia.org)
  • Therapeutic options in patients with advanced-stage gastroenteropancreatic (GEP) neuroendocrine tumors are limited. (snmjournals.org)
  • Participants come away from the conference with an understanding of standard management of patients with neuroendocrine tumors, as well as new diagnostic and therapeutic techniques. (nanets.org)
  • For the Neuroendocrine Tumors emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). (marketsampler.com)
  • The specific characters of peptides (high bioactivity, high specificity, and low toxicity) have made them attractive therapeutic agents. (intechopen.com)
  • Perhaps one of the most striking findings for this peptide receptor radionuclide therapy is the long median duration of progression-free survival. (ascopost.com)
  • It helps to reduce tumor size and prevent tumor proliferation, as well as reduce the signs and symptoms caused by the tumor. (intheranostics.com)
  • Dual-isotope combinations, or "tandem" approaches, may improve tolerability while retaining a high tumor dose. (bvsalud.org)